|
1
|
Global Burden of Disease Cancer
Collaboration, ; Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T,
Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E,
Anderson BO, et al: Global, regional, and national cancer
incidence, mortality, years of life lost, years lived with
disability, and disability-adjusted life-years for 29 cancer
groups, 1990 to 2016: A systematic analysis for the global burden
of disease study. JAMA Oncol. 4:1553–1568. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB, Marrero JA, Rudolph L and
Reddy KR: Diagnosis and treatment of hepatocellular carcinoma.
Gastroenterology. 134:1752–1763. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sirivatanauksorn Y and Tovikkai C:
Comparison of staging systems of hepatocellular carcinoma. HPB
Surg. 2011:8182172011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Barron CC, Bilan PJ, Tsakiridis T and
Tsiani E: Facilitative glucose transporters: Implications for
cancer detection, prognosis and treatment. Metabolism. 65:124–139.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ayala FR, Rocha RM, Carvalho KC, Carvalho
AL, da Cunha IW, Lourenço SV and Soares FA: GLUT1 and GLUT3 as
potential prognostic markers for Oral squamous cell carcinoma.
Molecules. 15:2374–2387. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Estilo CL, O-charoenrat P, Talbot S, Socci
ND, Carlson DL, Ghossein R, Williams T, Yonekawa Y, Ramanathan Y,
Boyle JO, et al: Oral tongue cancer gene expression profiling:
Identification of novel potential prognosticators by
oligonucleotide microarray analysis. BMC Cancer. 9:112009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Baer S, Casaubon L, Schwartz MR,
Marcogliese A and Younes M: Glut3 expression in biopsy specimens of
laryngeal carcinoma is associated with poor survival. Laryngoscope.
112:393–396. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Younes M, Brown RW, Stephenson M, Gondo M
and Cagle PT: Overexpression of Glut1 and Glut3 in stage I nonsmall
cell lung carcinoma is associated with poor survival. Cancer.
80:1046–1051. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Conde VR, Oliveira PF, Nunes AR, Rocha CS,
Ramalhosa E, Pereira JA, Alves MG and Silva BM: The progression
from a lower to a higher invasive stage of bladder cancer is
associated with severe alterations in glucose and pyruvate
metabolism. Exp Cell Res. 335:91–98. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pugh RN, Murray-Lyon IM, Dawson JL,
Pietroni MC and Williams R: Transection of the oesophagus for
bleeding oesophageal varices. Br J Surg. 60:646–649. 1973.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang JD, Hainaut P, Gores GJ, Amadou A,
Plymoth A and Roberts LR: A global view of hepatocellular
carcinoma: Trends, risk, prevention and management. Nat Rev
Gastroenterol Hepatol. 16:589–604. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hong SS, Kim TK, Sung KB, Kim PN, Ha HK,
Kim AY and Lee MG: Extrahepatic spread of hepatocellular carcinoma:
A pictorial review. Eur Radiol. 13:874–882. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tabrizian P, Jibara G, Shrager B, Schwartz
M and Roayaie S: Recurrence of hepatocellular cancer after
resection: Patterns, treatments, and prognosis. Ann Surg.
261:947–955. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chun YH, Kim SU, Park JY, Kim DY, Han KH,
Chon CY, Kim BK, Choi GH, Kim KS, Choi JS and Ahn SH: Prognostic
value of the 7th edition of the AJCC staging system as a clinical
staging system in patients with hepatocellular carcinoma. Eur J
Cancer. 47:2568–2575. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cillo U, Vitale A, Grigoletto F, Farinati
F, Brolese A, Zanus G, Neri D, Boccagni P, Srsen N, D'Amico F, et
al: Prospective validation of the Barcelona Clinic Liver Cancer
staging system. J Hepatol. 44:723–731. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ma WJ, Wang HY and Teng LS: Correlation
analysis of preoperative serum alpha-fetoprotein (AFP) level and
prognosis of hepatocellular carcinoma (HCC) after hepatectomy.
World J Surg Oncol. 11:2122013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamashita T, Forgues M, Wang W, Kim JW, Ye
Q, Jia H, Budhu A, Zanetti KA, Chen Y, Qin LX, et al: EpCAM and
alpha-fetoprotein expression defines novel prognostic subtypes of
hepatocellular carcinoma. Cancer Res. 68:1451–1461. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Villanueva A, Hoshida Y, Battiston C,
Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M,
Kumada H, et al: Combining clinical, pathology, and gene expression
data to predict recurrence of hepatocellular carcinoma.
Gastroenterology. 140:1501–1512.e2. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jin GZ, Yu WL, Dong H, Zhou WP, Gu YJ, Yu
H, Yu H, Lu XY, Xian ZH, Liu YK, et al: SUOX is a promising
diagnostic and prognostic biomarker for hepatocellular carcinoma. J
Hepatol. 59:510–517. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nault JC, De Reynies A, Villanueva A,
Calderaro J, Rebouissou S, Couchy G, Decaens T, Franco D, Imbeaud
S, Rousseau F, et al: A hepatocellular carcinoma 5-gene score
associated with survival of patients after liver resection.
Gastroenterology. 145:176–187. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gatenby RA and Gillies RJ: Why do cancers
have high aerobic glycolysis? Nat Rev Cancer. 4:891–899. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Macheda ML, Rogers S and Best JD:
Molecular and cellular regulation of glucose transporter (GLUT)
proteins in cancer. J Cell Physiol. 202:654–662. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Krzeslak A, Wojcik-Krowiranda K, Forma E,
Jozwiak P, Romanowicz H, Bienkiewicz A and Brys M: Expression of
GLUT1 and GLUT3 glucose transporters in endometrial and breast
cancers. Pathol Oncol Res. 18:721–728. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ha TK, Her NG, Lee MG, Ryu BK, Lee JH, Han
J, Jeong SI, Kang MJ, Kim NH, Kim HJ and Chi SG: Caveolin-1
increases aerobic glycolysis in colorectal cancers by stimulating
HMGA1-mediated GLUT3 transcription. Cancer Res. 72:4097–4109. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Boado RJ, Black KL and Pardridge WM: Gene
expression of GLUT3 and GLUT1 glucose transporters in human brain
tumors. Brain Res Mol Brain Res. 27:51–57. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Starska K, Forma E, Jozwiak P, Brys M,
Lewy-Trenda I, Brzezinska-Blaszczyk E and Krzeslak A: Gene and
protein expression of glucose transporter 1 and glucose transporter
3 in human laryngeal cancer-the relationship with regulatory
hypoxia-inducible factor-1α expression, tumor invasiveness, and
patient prognosis. Tumour Biol. 36:2309–2321. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Haber RS, Weinstein SP, O'Boyle E and
Morgello S: Tissue distribution of the human GLUT3 glucose
transporter. Endocrinology. 132:2538–2543. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Maratou E, Dimitriadis G, Kollias A,
Boutati E, Lambadiari V, Mitrou P and Raptis SA: Glucose
transporter expression on the plasma membrane of resting and
activated white blood cells. Eur J Clin Invest. 37:282–290. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lunt SY and Vander Heiden MG: Aerobic
glycolysis: Meeting the metabolic requirements of cell
proliferation. Annu Rev Cell Dev Biol. 27:441–464. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Warburg O, Wind F and Negelein E: The
metabolism of tumors in the body. J Gen Physiol. 8:519–530. 1927.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
O'Rourke JF, Pugh CW, Bartlett SM and
Ratcliffe PJ: Identification of hypoxically inducible mRNAs in HeLa
cells using differential-display PCR. Role of hypoxia-inducible
factor-1. Eur J Biochem. 241:403–410. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang HL, Wang MD, Zhou X, Qin CJ, Fu GB,
Tang L, Wu H, Huang S, Zhao LH, Zeng M, et al: Blocking
preferential glucose uptake sensitizes liver tumor-initiating cells
to glucose restriction and sorafenib treatment. Cancer Lett.
388:1–11. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Darnell JE Jr, Kerr IM and Stark GR:
Jak-STAT pathways and transcriptional activation in response to
IFNs and other extracellular signaling proteins. Science.
264:1415–1421. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhong Z, Wen Z and Darnell JE Jr: Stat3: A
STAT family member activated by tyrosine phosphorylation in
response to epidermal growth factor and interleukin-6. Science.
264:95–98. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Baumann MU, Zamudio S and Illsley NP:
Hypoxic upregulation of glucose transporters in BeWo
choriocarcinoma cells is mediated by hypoxia-inducible factor-1. Am
J Physiol Cell Physiol. 293:C477–C485. 2007. View Article : Google Scholar : PubMed/NCBI
|
